- ISSN 1672-5069
- CN 34-1270/R
- CODEN SGZHBF
Journal of Practical Hepatology ›› 2024, Vol. 27 ›› Issue (4): 494-510.
Previous Articles Next Articles
Chinese Society of Hepatology, Chinese Medical Association
Received:2024-05-07
Online:2024-07-10
Published:2024-07-10
Contact:
Fan Jiangao, Department of Gastroenterology, Xinhua Hospital Affiliated toShanghai Jiao Tong University School of Medicine, Shanghai 200092, China, Email: fanjiangao@xinhuamed.com.cn; Nan Yuemin,Department of Traditional and Western Medical Hepatology, HebeiMedical University Third Hospital , Shijiazhuang 050051, China, Email: nanyuemin@163.com; Wei Lai,Hepatopancreatobiliary Center, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, TsinghuaUniversity, Beijing 102218, China, Email: weilai@mail.tsinghua.edu.cn
Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of metabolic dysfunction-associated (non-alcoholic) fatty liver disease(Version 2024)[J]. Journal of Practical Hepatology, 2024, 27(4): 494-510.
| [1] Rinella ME,Neuschwander-Tetri BA,Siddiqui MS,et al.AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J].Hepatology,2023,77(5):1797-1835.DOI: 10.1097/HEP.0000000000000323. [2] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版)[J]. 中华肝脏病杂志,2018,26(3):195-203.DOI:10.3760/cma.j.issn.1007-3418.2018.03.008. [3] Riazi K,Azhari H,Charette JH,et al.The prevalence and incidence of NAFLD worldwide:a systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2022,7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. [4] Lou TW,Yang RX,Fan JG.The global burden of fatty liver disease: the major impact of China[J].Hepatobiliary Surg Nutr,2024,13(1):119-123.DOI: 10.21037/hbsn-23-556. [5] Cusi K,Isaacs S,Barb D,et al.American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD)[J].EndocrPract,2022,28(5):528-562.DOI:10.1016/j.eprac.2022.03.010. [6] Duell PB,Welty FK,Miller M,et al.Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American heart association[J].Arterioscler Thromb Vasc Biol,2022,42(6):e168-e185.DOI: 10.1161/ATV.0000000000000153. [7] Sun DQ, Targher G, Byrne CD, et al. An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease[J]. Hepatobiliary Surg Nutr. 2023;12(3):386-403. DOI: 10.21037/hbsn-22-421. [8] Nan Y, An J, Bao J, et al. The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease[J]. J Hepatol, 2021,75(2):454-461. DOI: 10.1016/j.jhep.2021.05.003. [9] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease[J]. Gastroenterology, 2020,158(7):1999-2014.e1. DOI: 10.1053/j.gastro.2019.11.312. [10] Eslam M, Newsome PN, Anstee QM, et al. A new definition for metabolic associated fatty liver disease: an international expert consensus statement[J]. J Hepatol, 2020,73(1):202-209.DOI: 10.1016/j.jhep.2020.03.039. [11] Eslam M, Sarin SK, Wong VW, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease[J]. Hepatol Int, 2020,14(6):889-919. DOI: 10.1007/s12072-020-10094-2. [12] Rinella ME, Lazarus JV, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. J Hepatol, 2023,79(6):1542-1556. DOI: 10.1016/j.jhep.2023.06.00. [13] Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease[J]. Cell, 2021,184(10):2537-2564. DOI: 10.1016/j.cell.2021.04.015. [14] DíazLA, Arab JP, Louvet A, et al. The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(12):764-783.DOI: 10.1038/s41575-023-00822-y. [15] Song SJ, Lai JC, Wong GL, et al. Can we use old NAFLD data under the new MASLD definition[J]? J Hepatol, 2024,80(2):e54-e56.DOI: 10.1016/j.jhep.2023.07.021. [16] Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review[J]. Hepatology, 2023,77(4):1335-1347.DOI: 10.1097/HEP.0000000000000004. [17] Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2023,8(1):20-30. DOI: 10.1016/S2468-1253(22)00317-X. [18] Ye Q, Zou B, Yeo YH, et al. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2020,5(8):739-752. DOI: 10.1016/S2468-1253(20)30077-7. [19] En Li Cho E, Ang CZ, Quek J, et al. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis[J]. Gut, 2023,72(11):2138-2148.DOI: 10.1136/gutjnl-2023-330110. [20] Ajmera V, Cepin S, Tesfai K, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes[J]. J Hepatol, 2023,78(3):471-478.DOI: 10.1016/j.jhep.2022.11.010. [21] Le MH, Le DM, Baez TC, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons[J]. Hepatol, 2023,79(2):287-295. DOI: 10.1016/j.jhep.2023.03.040. [22] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China[J]. Hepatology, 2020,71(5):1851-1864.DOI: 10.1002/hep.31150. [23] Zeng J, Yang RX, Pan Q, et al. Prevalence, clinical characterizations, risk factors and indicators for lean Chinese adults with nonalcoholic fatty liver disease[J]. World J Gastroenterol,2020,26(15):1792-1804.DOI: 10.3748/wjg.v26.i15.1792. [24] Zeng J, Qin L, Jin Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: A community-based study[J]. Hepatobiliary Pancreat Dis Int, 2022,21(2):154-161.DOI: 0.1016/j.hbpd.2022.01.006. [25] Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: Current evidence and opinion[J]. World J Gastroenterol, 2021,27(26):3971-3983. DOI: 10.3748/wjg.v27.i26.3971. [26] Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China[J]. Gastroenterology, 2023,165(4):1025-1040. DOI: 10.1053/j.gastro.2023.05.053. [27] Muzurovi E, Mikhailidis DP, Mantzoros C. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk[J]. Metabolism, 2021,119:154770. DOI: 10.1016/j.metabol.2021.154770. [28] Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease[J]? Hepatology, 2022, 76(5): 1423-1437.DOI: 10.1002/hep.32499. [29] Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease[J]. Hepatology, 2020,71(3):808-819. DOI: 10.1002/hep.31014. [30] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis[J]. J Hepatol, 2019,71(4):793-801. DOI: 10.1016/j.jhep.2019.06.021. [31] Sanyal AJ, Van Natta ML, Clark J, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease[J]. N Engl J Med, 2021,385(17):1559-1569. DOI: 10.1056/NEJMoa2029349. [32] Thomas JA, Kendall BJ, Dalais C,et al. Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Eur J Cancer, 2022,173:250-262. DOI: 10.1016/j.ejca.2022.06.051. [33] Paik JM, Golabi P, Younossi Y, et al. Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD[J]. Hepatology, 2020,72(5):1605-1616. DOI: 10.1002/hep.31173. [34] Männistö VT, Salomaa V, Färkkilä M, et al. Incidence of liver-related morbidity and mortality in a population cohort of non-alcoholic fatty liver disease[J]. Liver Int, 2021,41(11):2590-2600. DOI: 10.1111/liv.15004. [35] Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-Kidney-Metabolic health: a presidential advisory from the American Heart Association[J]. Circulation, 2023,148(20):1606-1635. DOI: 10.1161/CIR.0000000000001184. [36] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals[J]. Gut, 2021,70(5):962-969. DOI: 10.1136/gutjnl-2020-322572. [37] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis[J]. Gut, 2022,71(1):156-162.DOI: 10.1136/gutjnl-2020-323082. [38] Zou ZY, Fan JG. Incidence of chronic kidney disease in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2020,73(1):214-216. DOI: 10.1016/j.jhep.2020.03.003. [39] Toh JZK, Pan XH, Tay PWL, et al. A meta-analysis on the global prevalence, risk factors and screening of coronary heart disease in nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2022,20(11):2462-2473.e10. DOI: 10.1016/j.cgh.2021.09.021. [40] Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis[J]. Lancet Gastroenterol Hepatol, 2021,6(11):903-913. DOI: 10.1016/S2468-1253(21)00308-3. [41] Mantovani A, Petracca G, Csermely A, et al. Non-alcoholic fatty liver disease and risk of new-onset heart failure: an updated meta-analysis of about 11 million individuals[J]. Gut, 2022,gutjnl-2022-327672.DOI: 10.1136/gutjnl-2022-327672. [42] Tang ASP, Chan KE, Quek J, et al. Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals[J]. Clin Mol Hepatol, 2022,28(3):483-496.DOI: 10.3350/cmh.2021.0406. [43] Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study[J]. BMJ,2024,384:e076388. DOI: 10.1136/bmj-2023-076388. [44] van Kleef LA, Lu Z, Ikram MA, et al. Liver stiffness not fatty liver disease is associated with atrial fibrillation: The Rotterdam study[J]. J Hepatol, 2022,77(4):931-938. DOI: 10.1016/j.jhep.2022.05.030. [45] Xia M, Ma S, Huang Q, et al. NAFLD-related gene polymorphisms and all-cause and cause-specific mortality in an Asian population: the Shanghai Changfeng Study[J]. Aliment Pharmacol Ther, 2022,55(6):705-721.DOI: 10.1111/apt.16772. [46] Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(8):487-503.DOI: 10.1038/s41575-023-00754-7. [47] Mantovani A, Petracca G, Beatrice G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies[J]. Gut, 2022,71(4):778-788.DOI: 10.1136/gutjnl-2021-324191. [48] Wang Z, Zhao X, Chen S, et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China[J]. Clin Gastroenterol Hepatol, 2021,19(4):788-796.e4.DOI: 10.1016/j.cgh.2020.05.009. [49] Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach[J]? Gut,2022,71(2):382-390. DOI: 10.1136/gutjnl-2020-322564. [50] Ren TY, Fan JG. What are the clinical settings and outcomes of lean NAFLD[J]? Nat Rev Gastroenterol Hepatol, 2021,18(5):289-290. DOI: 10.1038/s41575-021-00433-5. [51] van Kleef LA, Choi HSJ, Brouwer WP, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B[J]. JHEP Rep, 2021, 3(5): 100350.DOI: 10.1016/j.jhepr.2021.100350. [52] Li G, Zhang X, Lin H, Liang LY, Wong GL, Wong VW. Non-invasive tests of non-alcoholic fatty liver disease[J]. Chin Med J (Engl), 2022,135(5):532-546. DOI: 10.1097/CM9.0000000000002027. [53] Cao YT, Xiang LL, Qi F,et al. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. EClinicalMedicine, 2022,51:101547.DOI: 10.1016/j.eclinm.2022.101547. [54] Qu Y, Song YY, Chen CW, et al. Diagnostic performance of FibroTouch ultrasound attenuation parameter and liver stiffness measurement in assessing hepatic steatosis and fibrosis in patients with nonalcoholic fatty liver disease[J]. Clin Transl Gastroenterol, 2021,12(4):e00323. DOI: 10.14309/ctg.0000000000000323. [55] Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis[J]. J Hepatol,2017,66(5):1022-1030. DOI: 10.1016/j.jhep.2016.12.022. [56] Caussy C, Brissot J, Singh S, et al. Prospective, same-day, direct comparison of controlled attenuation parameter with the M vs the XL probe in patients with nonalcoholic fatty liver disease, using magnetic resonance imaging-proton density fat fraction as the standard[J]. Clin Gastroenterol Hepatol,2020,18(8):1842-1850.e6.DOI: 10.1016/j.cgh.2019.11.060. [57] Petroff D, Blank V, Newsome PN, et al. Assessment of hepatic steatosis by controlled attenuation parameter using the M and XL probes: an individual patient data meta-analysis[J]. Lancet Gastroenterol Hepatol,2021,6(3):185-198. DOI: 10.1016/S2468-1253(20)30357-5. [58] Jung J, Han A, Madamba E, et al. Direct comparison of quantitative US versus controlled attenuation parameter for liver fat assessment using MRI proton density fat fraction as the reference standard in patients suspected of having NAFLD[J]. Radiology,2022,304(1):75-82. DOI: 10.1148/radiol.211131. [59] Gu J, Liu S, Du S et al. Diagnostic value of MRI-PDFF for hepatic steatosis in patients with non-alcoholic fatty liver disease: a meta-analysis[J]. EurRadiol,2019,29(7):3564-3573.DOI: 10.1007/s00330-019-06072-4. [60] Anstee QM, Castera L, Loomba R. Impact of non-invasive biomarkers on hepatology practice: Past, present and future[J]. J Hepatol,2022,76(6):1362-1378.DOI: 10.1016/j.jhep.2022.03.026. [61] Zhang H, Rios RS, Boursier J, et al. Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study[J]. Chin Med J (Engl), 2023,136(3):341-350. DOI: 10.1097/CM9.0000000000002603. [62] Masoodi M, Gastaldelli A, Hyötyläinen T, et al. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests[J]. Nat Rev Gastroenterol Hepatol,2021,18(12):835-856. DOI: 10.1038/s41575-021-00502-9. [63] van Kleef LA, Sonneveld MJ, de Man RA, et al. Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline[J]. J Hepatol, 2022,76(1):245-246. DOI:10.1016/j.jhep.2021.08.017. [64] Shen F, Mi YQ, Xu L, et al. Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis[J]. Aliment Pharmacol Ther,2019,50(1):93-102. DOI: 10.1111/apt.15298. [65] Chan WK, Treeprasertsuk S, Goh GB, et al. Optimizing use of nonalcoholic fatty liver disease fibrosis score, Fibrosis-4 score, and liver stiffness measurement to identify patients with advanced fibrosis[J]. Clin Gastroenterol Hepatol,2019,17(12):2570-2580.e37. DOI: 10.1016/j.cgh.2019.03.006. [66] Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis[J]. Gut,2022,71(5):1006-1019. DOI: 10.1136/gutjnl-2021-324243. [67] Shi YW, He FP, Chen JJ, et al. Metabolic disorders combined with noninvasive tests to screen advanced fibrosis in nonalcoholic fatty liver disease[J]. J Clin Transl Hepatol. 2021,9(5):607-614. DOI: 10.14218/JCTH.2021.00058. [68] Sanyal AJ, Foucquier J, Younossi ZM, et al. Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores[J]. J Hepatol,2023,78(2):247-259. DOI: 10.1016/j.jhep.2022.10.034. [69] Pennisi G, Enea M, Falco V, et al. Noninvasive assessment of liver disease severity in patients with nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes[J]. Hepatology,2023,78(1):195-211. DOI: 10.1097/HEP.0000000000000351. [70] Duan WJ, Wang XZ, Ma AL, et al. Multicenter prospective study to validate a new transient elastography device for staging liver fibrosis in patients with chronic hepatitis B[J]. J Dig Dis,21(9):519-525. DOI: 10.1111/1751-2980.12924. [71] Liang JX, Ampuero J, Niu H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography[J]. J Hepatol, 2023,79(3):592-604.DOI: 10.1016/j.jhep.2023.04.025. [72] Newsome PN, Sasso M, Deeks JJ, et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol,2020,5(4):362-373. DOI: 10.1016/S2468-1253(19)30383-8. [73] Imajo K, Saigusa Y, Kobayashi T, et al. M-PAST score is better than MAST score for the diagnosis of active fibrotic nonalcoholic steatohepatitis[J]. Hepatol Res,2023,53(9):844-856. DOI: 10.1111/hepr.13927. [74] Taylor-Weiner A, Pokkalla H, Han L, et al. A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH[J]. Hepatology, 2021,74(1):133-147. DOI: 10.1002/hep.31750. [75] Loomba R, Lim JK, Patton H,et al.AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review[J]. Gastroenterology, 2020, 158(6):1822-1830.DOI: 10.1053/j.gastro.2019.12.053. [76] Papatheodoridi M, Hiriart JB, Lupsor-Platon M, et al. Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease[J]. J Hepatol, 2021,74(5):1109-1116. DOI: 10.1016/j.jhep.2020.11.050. [77] 中国健康促进基金会脂肪肝防治专项基金专家委员会, 中国医药生物技术协会慢病管理分会.代谢相关脂肪性肝病健康管理服务包(简版)[J].中华健康管理学杂志,2023,17(3):169-179. DOI: 10.3760/cma.j.cn115624-20230112-00026. [78] 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中华健康管理学杂志, 2019, 13(1): 7-26. DOI: 10.3760/cma.j.issn.0253?9624.2019.01.004. [79] Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease[J]. United European Gastroenterol J,2024,12(2):177-186.DOI: 10.1002/ueg2.12525. [80] Younossi ZM, Zelber-Sagi S, Henry L,et al. Lifestyle interventions in nonalcoholic fatty liver disease[J]. Nat Rev Gastroenterol Hepatol,2023,20(11):708-722. DOI: 10.1038/s41575-023-00800-4. [81] Balakrishnan M, Liu K, Schmitt S, et al. Behavioral weight-loss interventions for patients with NAFLD: A systematic scoping review[J]. Hepatol Commun, 2023,7(8):e0224.DOI: 10.1097/HC9.0000000000000224. [82] Chai XN, Zhou BQ, Ning N, et al. Effects of lifestyle intervention on adults with metabolic associated fatty liver disease: A systematic review and meta-analysis[J]. Front Endocrinol (Lausanne), 2023,14:1081096. DOI: 10.3389/fendo.2023.1081096. [83] Abdallah J, Assaf S, Das A, et al. Effects of anti-inflammatory dietary patterns on non-alcoholic fatty liver disease: a systematic literature review[J]. Eur J Nutr,2023,62(4):1563-1578.DOI: 10.1007/s00394-023-03085-0. [84] Tsompanaki E, Thanapirom K, Papatheodoridi M, et al. Systematic review and meta-analysis: the role of diet in the development of nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol,2023,21(6):1462-1474.e24.DOI: 10.1016/j.cgh.2021.11.026. [85] Henney AE, Gillespie CS, Alam U,et al. Ultra-processed food intake is associated with non-alcoholic fatty liver disease in adults: a systematic review and meta-analysis[J]. Nutrients,2023,15(10):2266.DOI: 10.3390/nu15102266. [86] Haigh L, Kirk C, El Gendy K, et al. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis[J]. Clin Nutr,2022,41(9):1913-1931.DOI: 10.1016/j.clnu.2022.06.037. [87] Hadefi A, Arvanitakis M, Trépo E, et al. Dietary strategies in non-alcoholic fatty liver disease patients: From evidence to daily clinical practice, a systematic review[J]. United European Gastroenterol J, 2023,11(7):663-689.DOI: 10.1002/ueg2.12443. [88] Del Bo' C, Perna S, Allehdan S, et al. Does the mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials[J]. Nutrients, 2023,15(10):2250.DOI: 10.3390/nu15102250. [89] Lange M, Nadkarni D, Martin L, et al. Intermittent fasting improves hepatic end points in nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Hepatol Commun,2023,7(8):e0212.DOI: 10.1097/HC9.0000000000000212. [90] Nam H, Yoo JJ, Cho Y, et al. Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis[J]. Dig Liver Dis, 2023,55(9):1178-1186. DOI: 10.1016/j.dld.2022.12.013. [91] Ghaffari M, Sadeghiyan S, Faramarzi M, et al. The effect of aerobic exercise on metabolic parameters of patients with non-alcoholic fatty liver disease: systematic review and meta-analysis[J]. J Sports Med Phys Fitness, 2023,63(1):178-187. DOI: 10.23736/S0022-4707.22.13801-6. [92] Stine JG, DiJoseph K, Pattison Z, et al. Exercise training is associated with treatment response in liver fat content by magnetic resonance imaging independent of clinically significant body weight loss in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Am J Gastroenterol,2023,118(7):1204-1213.DOI: 10.14309/ajg.0000000000002098. [93] Yu X, Wang Y, Lai J, et al. Comparative efficacy of exercise training processes in improving nonalcoholic fatty liver disease: a systematic review and meta-analysis[J]. Ir J Med Sci, 2023,192(1):131-142.DOI: 10.1007/s11845-022-02988-x. [94] Chen G, Banini BA, Do A, et al. Exercise does not independently improve histological outcomes in biopsy-proven non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Genes (Basel),2023,14(9):1811.DOI: 10.3390/genes14091811. [95] Houttu V, Bouts J, Vali Y, et al. Does aerobic exercise reduce NASH and liver fibrosis in patients with non-alcoholic fatty liver disease? A systematic literature review and meta-analysis[J]. Front Endocrinol (Lausanne), 2022,13:1032164.DOI: 10.3389/fendo.2022.1032164. [96] Chen G, Banini B, Do A, et al. The independent effect of exercise on biopsy-proven non-alcoholic fatty liver disease: A systematic review[J]. Clin Mol Hepatol, 2023,29(Suppl):S319-S332.DOI: 10.3350/cmh.2022.0366. [97] Zhang X, Goh GB, Chan WK, et al. Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease[J]. Liver Int, 2020,40(11):2719-2731. DOI: 10.1111/liv.14638. [98] Muftah AA, Banala C, Raasikh T, et al. Telehealth interventions in patients with chronic liver diseases: A systematic review[J]. Hepatology, 2023,78(1):179-194.DOI: 10.1097/HEP.0000000000000265. [99] 孙超,范建高.移动医疗应用程序干预非酒精性脂肪性肝病患者生活方式的效果[J]. 中华健康管理学杂志,2023,17(10):796-800. DOI: 10.3760/cma.j.cn115624-20230615-00374. [100] Liao C, Liang X, Zhang X, et al. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. PLoS One,2023,18(8):e0289616.DOI: 10.1371/journal.pone.0289616. [101] Park MJ, Kim H, Kim MG, et al. Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis[J]. Clin Mol Hepatol, 2023,29(3):693-704.DOI: 10.3350/cmh.2022.0330. [102] Huang Y, Wang X, Yan C, et al. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology[J]. Medicine (Baltimore), 2022,101(43):e31437.DOI: 10.1097/MD.0000000000031437. [103] Raj H, Durgia H, Palui R, et al. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review[J]. World J Diabetes,2019,10(2):114-132.DOI: 10.4239/wjd.v10.i2.114. [104] Jin Z, Yuan Y, Zheng C, et al. Effects of sodium-glucose co-transporter 2 inhibitors on liver fibrosis in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: An updated meta-analysis of randomized controlled trials[J]. J Diabetes Complications, 2023,37(8):108558.DOI: 10.1016/j.jdiacomp.2023.108558. [105] Hameed I, Hayat J, Marsia S, et al. Comparison of sodium-glucose cotransporter-2 inhibitors and thiazolidinediones for management of non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2023,47(5):102111.DOI: 10.1016/j.clinre.2023.102111. [106] Zafar Y, Rashid AM, Siddiqi AK, et al. Effect of novel glucose lowering agents on non-alcoholic fatty liver disease: A systematic review and meta-analysis[J]. Clin Res Hepatol Gastroenterol, 2022,46(7):101970.DOI: 10.1016/j.clinre.2022.101970. [107] Wang Z, Du H, Zhao Y, et al. Response to pioglitazone in non-alcoholic fatty liver disease patients with vs. without type 2 diabetes: A meta-analysis of randomized controlled trials[J]. Front Endocrinol (Lausanne), 2023,14:1111430.DOI: 10.3389/fendo.2023.1111430. [108] Gu Y, Sun L, He Y, et al. Comparative efficacy of glucagon-like peptide 1 (GLP-1) receptor agonists, pioglitazone and vitamin E for liver histology among patients with nonalcoholic fatty liver disease: systematic review and pilot network meta-analysis of randomized controlled trials[J]. Expert Rev Gastroenterol Hepatol, 2023,17(3):273-282.DOI: 10.1080/17474124.2023.2172397. [109] 中国医药生物技术协会慢病管理分会.肝硬化合并糖尿病患者血糖管理专家共识[J].中华糖尿病杂志,2022,14(8):749-763. DOI: 10.3760/cma.j.cn115791-20220624-00291. [110] Abdallah M, Brown L, Provenza J, et al. Safety and efficacy of dyslipidemia treatment in NAFLD patients: a meta-analysis of randomized controlled trials[J]. Ann Hepatol, 2022,27(6):100738.DOI: 10.1016/j.aohep.2022.100738. [111] Dai W, Xu B, Li P,et al. Statins for the Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis[J]. Am J Ther, 2023,30(1):e17-e25.DOI: 10.1097/MJT.0000000000001499. [112] Ayada I, van Kleef LA, Zhang H, et al. Dissecting the multifaceted impact of statin use on fatty liver disease: a multidimensional study[J]. EBioMedicine, 2023,87:104392.DOI: 10.1016/j.ebiom.2022.104392. [113] Zeng RW, Yong JN, Tan DJH, et al. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin[J]. Aliment Pharmacol Ther, 2023,57(6):600-609.DOI: 10.1111/apt.17371. [114] Pose E, Napoleone L, Amin A, et al. Safety of two different doses of simvastatin plus rifaximin in decompensated cirrhosis (LIVERHOPE-SAFETY): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Gastroenterol Hepatol,2020,5(1):31-41.DOI: 10.1016/S2468-1253(19)30320-6. [115] 徐清扬,范建高. 肾素-血管紧张素系统抑制剂治疗非酒精性脂肪性肝病的研究进展[J]. 肝脏,2022,27(11):1161-1163. DOI: 10.3969/j.issn.1008-1704.2022.11.004. [116] Ramandi A, George J, Merat S, et al. Polypill protects MAFLD patients from cardiovascular events and mortality: a prospective trial[J]. Hepatol Int, 2023,17(4):882-888. DOI: 10.1007/s12072-023-10542-9. [117] Zhang X, Wong GL, Yip TC, et al.Angiotensin-converting enzyme inhibitors prevent liver-related events in nonalcoholic fatty liver disease[J]. Hepatology, 2022,76(2):469-482. DOI: 10.1002/hep.32294. [118] Simon TG, Wilechansky RM, Stoyanova S, et al. Aspirin for Metabolic Dysfunction–Associated Steatotic Liver Disease Without Cirrhosis: A Randomized Clinical Trial[J]. JAMA, 2024,331(11):920–929.DOI: 10.1001/jama.2024.1215. [119] Abdel-Maboud M, Menshawy A, Menshawy E, et al. The efficacy of vitamin E in reducing non-alcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression[J]. Therap Adv Gastroenterol, 2020, 13:1756284820974917.DOI: 10.1177/1756284820974917. [120] Vogli S, Naska A, Marinos G, et al. The effect of vitamin E supplementation on serum aminotransferases in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis[J]. Nutrients, 2023,15(17):3733.DOI: 10.3390/nu15173733. [121] Ng CH, Tang ASP, Xiao J, et al. Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals[J]. Hepatol Commun, 2023,7(3):e0005.DOI: 10.1097/HC9.0000000000000005. [122] Harrison SA, Bedossa P, Guy CD, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis[J]. N Engl J Med, 2024,390(6):497-509.DOI: 10.1056/NEJMoa2309000. [123] Francque SM, Bedossa P, Ratziu V, et al. A randomized, controlled trial of the Pan-PPAR agonist Lanifibranor in NASH[J]. N Engl J Med, 2021,385(17):1547-1558. DOI: 10.1056/NEJMoa2036205. [124] Harrison SA, Frias JP, Neff G, et al. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial[J]. Lancet Gastroenterol Hepatol, 2023,8(12):1080-1093. DOI: 10.1016/S2468-1253(23)00272-8. [125] Loomba R, Sanyal AJ, Kowdley KV, et al. Randomized, controlled trial of the FGF21 analogue Pegozafermin in NASH[J]. N Engl J Med, 2023,389(11):998-1008. DOI: 10.1056/NEJMoa2304286. [126] Romero-Gómez M, Lawitz E, Shankar RR, et al. A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2023,79(4):888-897. DOI: 10.1016/j.jhep.2023.05.013. [127] Hartman ML, Sanyal AJ, Loomba R, et al. Effects of novel dual GIP and GLP-1 receptor agonist Tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes[J]. Diabetes Care, 2020,43(6):1352-1355. DOI: 10.2337/dc19-1892. [128] Ledford H. First US drug approved for a liver disease surging around the world[J]. Nature, 2024, DOI: 10.1038/d41586-024-00747-9. [129] Kalopitas G, Antza C, Doundoulakis I, et al. Impact of Silymarin in individuals with nonalcoholic fatty liver disease: A systematic review and meta-analysis[J]. Nutrition, 2021,83:111092.DOI: 10.1016/j.nut.2020.111092. [130] Dajani AI, Popovic B. Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: A systematic review and network meta-analysis[J]. World J Clin Cases, 2020,8(21):5235-5249.DOI: 10.12998/wjcc.v8.i21.5235. [131] Lin X, Mai M, He T, et al. Efficiency of ursodeoxycholic acid for the treatment of nonalcoholic steatohepatitis: A systematic review and meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2022,16(6):537-545.DOI: 10.1080/17474124.2022.2083605. [132] Wang G, Huang Y, Yang H, et al. Impacts of bariatric surgery on adverse liver outcomes: a systematic review and meta-analysis[J]. Surg ObesRelat Dis,2023,19(7):717-726.DOI: 10.1016/j.soard.2022.12.025. [133] de Barros F, Cardoso Faleiro Uba PH. Liver transplantation and bariatric surgery: a new surgical reality: a systematic review of the best time for bariatric surgery[J]. Updates Surg, 2021,73(5):1615-1622.DOI: 10.1007/s13304-021-01106-3. [134] Manzano-Nunez R, Rivera-Esteban J, Comas M, et al. Outcomes of patients with severe obesity and cirrhosis with portal hypertension undergoing bariatric surgery: a systematic review[J]. Obes Surg,2023,33(1):224-233.DOI: 10.1007/s11695-022-06362-9. [135] Younossi ZM, Stepanova M, Al Shabeeb R, et al. The changing epidemiology of adult liver transplantation in the United States in 2013-2022: The dominance of metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease[J]. Hepatol Commun, 2023,8(1):e0352. DOI: 10.1097/HC9.0000000000000352. [136] Yong JN, Lim WH, Ng CH, et al. Outcomes of nonalcoholic steatohepatitis after liver transplantation: An updated meta-analysis and systematic review[J]. Clin Gastroenterol Hepatol,2023,21(1):45-54.e6.DOI: 10.1016/j.cgh.2021.11.014. [137] Tan HC, Shumbayawonda E, Beyer C, et al. Multiparametric magnetic resonance imaging and magnetic resonance elastography to evaluate the early effects of bariatric surgery on nonalcoholic fatty liver disease[J]. Int J Biomed Imaging, 2023,2023:4228321. DOI: 10.1155/2023/4228321. [138] Semmler G, Yang Z, Fritz L, et al. Dynamics in liver stiffness measurements predict outcomes in advanced chronic liver disease[J]. Gastroenterology,2023,165(4):1041-1052. DOI: 10.1053/j.gastro.2023.06.030. [139] Lee SW, Huang DQ, Bettencourt R, et al. Low liver fat in non-alcoholic steatohepatitis-related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality[J]. Aliment Pharmacol Ther, 2024,59(1):80-88. DOI: 10.1111/apt.17783. [140] Lin H, Lee HW, Yip TC, et al. Vibration-controlled transient elastography scores to predict liver-related events in steatotic liver disease[J]. JAMA,2024, e241447. DOI: 10.1001/jama.2024.1447. [141] Shi YW, Fan JG. Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis[J]. Clin Mol Hepatol, 2023,29(Suppl):S228-S243.DOI: 10.3350/cmh.2022.0401. [142] Huang R, Fan JG, Shi JP, et al. Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey[J]. Health Qual Life Outcomes, 2021,19(1):140. DOI: 10.1186/s12955-021-01778-w. [143] Sun C, Fan JG. Editorial: changes of health-related quality of life associated with liver disease severity and its improvement after treatment in NAFLD[J]. Aliment Pharmacol Ther, 2023,57(2):257-258. DOI: 10.1111/apt.17318. [144] Chang XJ, Shi YW, Wang J, et al. Influence of weight management on the prognosis of steatohepatitis in chronic hepatitis B patients during antiviral treatment[J]. Hepatobiliary Pancreat Dis Int, 2021,20(5):416-425.DOI: 10.1016/j.hbpd.2021.06.009. [145] Liu H, Qi J, Yang J, et al. Burden of liver complications related to non-alcoholic fatty liver disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019[J]. Diabetes ObesMetab, 2023,25 Suppl 1:43-52. DOI: 10.1111/dom.15010. [146] Yip TC, Fan JG, Wong VW. China's fatty liver crisis: A looming public health emergency[J]. Gastroenterology, 2023,165(4):825-827.DOI: 10.1053/j.gastro.2023.06.008. [147] Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement[J]. Nat Rev Gastroenterol Hepatol, 2022,19(1):60-78. DOI: 10.1038/s41575-021-00523-4. [148] Lazarus JV, Mark HE, Allen AM, et al. A global research priority agenda to advance public health responses to fatty liver disease[J]. J Hepatol, 2023,79(3):618-634. DOI: 10.1016/j.jhep.2023.04.035. [149] Sarin SK, Eslam M, Fan JG, et al. MAFLD, patient-centred care, and APASL[J]. Hepatol Int, 2022,16(5):1032-1034. DOI: 10.1007/s12072-022-10408-6. [150] Marchesini G, Vettor R, Pinzani M. MASLD emerging from the fog of fatty liver[J]. J Hepatol, 2024,80(2):178-180. DOI: 10.1016/j.jhep.2023.10.011. [151] Lonardo A, Bril F, Caldwell SH, et al. Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature[J]. J Hepatol, 2024,S0168-8278(24)00054-0. DOI: 10.1016/j.jhep.2024.01.012. [152] Zeng J, Jin Q, Yang J, et al. Prevalence and incidence of MAFLD and associated anthropometric parameters among prepubertal children of the Shanghai Birth Cohort[J]. Hepatol Int, 2023,17(6):1416-1428. DOI: 10.1007/s12072-023-10574-1. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
